$CARM
Carisma Therapeutics Inc Stock $carm

$carm Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000148500319000065 Filed on August 08, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.240M	$2.620M	$2.350M
YoY Change	-15.4%	11.49%	4.91%
% of Gross Profit
Research & Development	$6.613M	$7.944M	$2.779M
YoY Change	96.12%	185.86%	-4.47%
% of Gross Profit
Depreciation & Amortization	$50.00K	$60.00K	$50.00K
YoY Change	-16.67%	20.0%	-44.44%
% of Gross Profit
Operating Expenses	$13.45M	$54.56M	$9.030M
YoY Change	-6.57%	504.22%	22.86%
Operating Profit	-$13.45M	-$54.56M	-$9.030M
YoY Change	-6.57%	504.22%	22.86%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$319.0K	$226.0K	$72.00K
YoY Change	-16.49%	213.89%	111.76%
Pretax Income	-$13.13M	-$54.34M	-$8.960M
YoY Change	-6.35%	506.47%	22.4%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$13.13M	-$54.34M	-$8.958M
YoY Change	-6.3%	506.55%	22.44%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.67
Diluted Earnings Per Share	-$129.7K	-$0.67	-$158.8K
COMMON SHARES
Basic Shares Outstanding	101.3M shares	80.74M shares	48.39M shares
Diluted Shares Outstanding		80.74M shares

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$57.90M	$64.90M	$63.00M
YoY Change	0.0%	3.02%	298.73%
Cash & Equivalents	$57.90M	$64.93M	$62.96M
Short-Term Investments
Other Short-Term Assets	$1.500M	$2.600M	$800.0K
YoY Change	0.0%	225.0%	14.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$59.41M	$67.53M	$63.77M
YoY Change	0.05%	5.9%	287.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$294.0K	$376.0K	$421.0K
YoY Change	-19.45%	-10.69%	-33.39%
Goodwill	$13.06M	$13.06M	$13.06M
YoY Change	0.0%	0.0%	-24.79%
Intangibles	$46.40M	$46.40M	$46.40M
YoY Change	0.0%	0.0%	-23.31%
Long-Term Investments
YoY Change
Other Assets	$208.0K	$223.0K	$41.00K
YoY Change	240.98%	443.9%	-46.75%
Total Long-Term Assets	$59.99M	$60.08M	$59.95M
YoY Change	0.13%	0.23%	-23.72%
TOTAL ASSETS
Total Short-Term Assets	$59.41M	$67.53M	$63.77M
Total Long-Term Assets	$59.99M	$60.08M	$59.95M
Total Assets	$119.4M	$127.6M	$123.7M
YoY Change	0.09%	3.15%	30.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.583M	$2.176M	$1.310M
YoY Change	85.69%	66.11%	5.22%
Accrued Expenses	$6.350M	$5.630M	$3.223M
YoY Change	22.82%	74.68%	29.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.092M	$7.948M	$4.533M
YoY Change	38.58%	75.34%	17.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$311.0K	$367.0K	$288.0K
YoY Change	0.0%	27.43%	94.59%
Total Long-Term Liabilities	$311.0K	$367.0K	$288.0K
YoY Change	0.0%	27.43%	94.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.092M	$7.948M	$4.533M
Total Long-Term Liabilities	$311.0K	$367.0K	$288.0K
Total Liabilities	$116.9M	$8.315M	$4.821M
YoY Change	1601.56%	72.47%	20.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$260.0M	-$246.8M	-$165.3M
YoY Change	44.99%	49.33%	20.94%
Common Stock	$101.0K	$101.0K	$77.00K
YoY Change	31.17%	31.17%	208.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.467M	$15.37M	$64.06M
YoY Change
Total Liabilities & Shareholders Equity	$119.4M	$127.6M	$123.7M
YoY Change	0.09%	3.15%	30.16%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$13.13M	-$54.34M	-$8.958M
YoY Change	-6.3%	506.55%	22.44%
Depreciation, Depletion And Amortization	$50.00K	$60.00K	$50.00K
YoY Change	-16.67%	20.0%	-44.44%
Cash From Operating Activities	-$6.980M	-$8.750M	-$5.600M
YoY Change	34.23%	56.25%	24.17%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$40.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$100.0K	-$40.00K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$3.400M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	31.29M	48.88M
YoY Change	-100.0%	-35.99%
NET CHANGE
Cash From Operating Activities	-6.980M	-8.750M	-5.600M
Cash From Investing Activities	-100.0K	-40.00K	0.000
Cash From Financing Activities	0.000	31.29M	48.88M
Net Change In Cash	-7.080M	22.50M	43.28M
YoY Change	38.55%	-48.01%	-1057.52%
FREE CASH FLOW
Cash From Operating Activities	-$6.980M	-$8.750M	-$5.600M
Capital Expenditures	-$100.0K	-$40.00K
Free Cash Flow	-$6.880M	-$8.710M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001485003
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	101265896	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1487000	USD
CY2018Q2	ebio	Stock Issued During Period Exercise Of Warrants Value StockIssuedDuringPeriodExerciseOfWarrantsValue	6918000	USD
CY2019Q2	ebio	Stock Issued During Period Exercise Of Warrants Value StockIssuedDuringPeriodExerciseOfWarrantsValue	3434000	USD
CY2019Q2	ebio	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	3400000	shares
	ebio	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	3361115	shares
CY2019Q2	ebio	Working Capital Net WorkingCapitalNet	59600000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1367000	USD
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4746000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5630000	USD
	dei	Entity Registrant Name EntityRegistrantName	Sesen Bio, Inc.
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.47
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2176000	USD
	ebio	Class Of Warrant Or Right Issued During The Period ClassOfWarrantOrRightIssuedDuringThePeriod	20410000	shares
	ebio	Class Of Warrant Or Right Number Of Expirations During The Period ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod	0	shares
CY2018Q1	ebio	Class Of Warrant Or Right Price Per Share ClassOfWarrantOrRightPricePerShare	0.125
CY2019Q2	ebio	Common Stock And Warrant Or Rights Price Per Share CommonStockAndWarrantOrRightsPricePerShare	1.47
CY2018Q1	ebio	Stock Issued During Period Exercise Of Warrants Value StockIssuedDuringPeriodExerciseOfWarrantsValue	336000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	464000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	615000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	230154000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	262107000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	401000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	285000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	326000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	356000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	63000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	274000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-16000	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13335458	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13335458	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32085561	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32085561	shares
CY2018Q4	us-gaap	Assets Assets	111561000	USD
CY2019Q2	us-gaap	Assets Assets	127612000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	51756000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	67529000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3900000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2700000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	44000000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	43000000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	48400000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	91400000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	119000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50422000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64900000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64931000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14690000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62981000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50442000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64951000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48291000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14509000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.20
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7968128	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	20410000	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9257632	shares
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26306517	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77456180	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101265896	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77456180	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101265896	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	77000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	101000	USD
CY2018Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	2928000	USD
CY2019Q2	us-gaap	Construction Payable Current ConstructionPayableCurrent	3758000	USD
CY2018Q2	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2019Q2	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12528000	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12528000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	101000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	107000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1045000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	906000	USD
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2351000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4303000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2617000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5672000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	13064000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	13064000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	403000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	809000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-517000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	961000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	426000	USD
	us-gaap	Revenues Revenues	0	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	46400000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	46400000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	124000	USD
	us-gaap	Lease Cost LeaseCost	275000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	189000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	113000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	76000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111561000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127612000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6113000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7948000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58265000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31295000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9979000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16743000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-3963000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-8958000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12921000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6480000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-54335000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-60815000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	72000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	116000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	226000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	487000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	9030000	USD
	us-gaap	Operating Expenses OperatingExpenses	13037000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	54561000	USD
	us-gaap	Operating Expenses OperatingExpenses	61302000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9030000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13037000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-54561000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61302000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	71000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	146000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	180000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	76071000	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	223000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	142000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	313000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	367000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	72000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	116000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	226000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	487000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	43000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1334000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2598000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	58226000	USD
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3400000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31243000	USD
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	5000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	45000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	10000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	7000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7300000	USD
CY2019Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3400000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	321000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	376000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2779000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6034000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7944000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12630000	USD
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	20000	USD
CY2019Q2	us-gaap	Restricted Cash RestrictedCash	20000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	20000	USD
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	20000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186024000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246800000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246839000	USD
CY2018Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	236480000	USD
CY2019Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	558018	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	650000	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.60
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.50
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	425000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2425115	shares
CY2018Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	9000000	USD
CY2018Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	41900000	USD
CY2019Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	28000000	USD
CY2018Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7968128	shares
CY2018Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	25555556	shares
CY2019Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	20410000	shares
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.13
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	285000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	686000	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	355000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	682000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1189418	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.86
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3941947	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5779044	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.12
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.30
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.93
CY2019Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	53000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	129000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	10000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9040000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	41932000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27809000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	45000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	18034000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	23858000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	64064000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	44207000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	38060000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	15369000	USD
CY2018Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	278000	USD
CY2019Q2	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	344000	USD
CY2018Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2019Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56421000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46105000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80739000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	79107000	shares

Files In Submission

Name	View Source	Status
0001485003-19-000065-index-headers.html	Edgar Link	pending
0001485003-19-000065-index.html	Edgar Link	pending
0001485003-19-000065.txt	Edgar Link	pending
0001485003-19-000065-xbrl.zip	Edgar Link	pending
ebio-20190630.xml	Edgar Link	completed
ebio-20190630.xsd	Edgar Link	pending
ebio-20190630_cal.xml	Edgar Link	unprocessable
ebio-20190630_def.xml	Edgar Link	unprocessable
ebio-20190630_lab.xml	Edgar Link	unprocessable
ebio-20190630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
glenmacdonaldebioemploym.htm	Edgar Link	pending
glenmacdonaldebioemploym001.jpg	Edgar Link	pending
glenmacdonaldebioemploym002.jpg	Edgar Link	pending
glenmacdonaldebioemploym003.jpg	Edgar Link	pending
glenmacdonaldebioemploym004.jpg	Edgar Link	pending
glenmacdonaldebioemploym005.jpg	Edgar Link	pending
glenmacdonaldebioemploym006.jpg	Edgar Link	pending
glenmacdonaldebioemploym007.jpg	Edgar Link	pending
glenmacdonaldebioemploym008.jpg	Edgar Link	pending
glenmacdonaldebioemploym009.jpg	Edgar Link	pending
glenmacdonaldebioemploym010.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sesenbio-dkimconsultingagr.htm	Edgar Link	pending
sesenbio-dkimseparationagr.htm	Edgar Link	pending
sesn-063019x10q.htm	Edgar Link	pending
sesn-063019x311.htm	Edgar Link	pending
sesn-063019x312.htm	Edgar Link	pending
sesn-063019x321.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CARM
Carisma Therapeutics Inc Stock $carm

2019 Q3 Form 10-Q Financial Statement

#000148500319000065 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM Carisma Therapeutics Inc Stock $carm

2019 Q3 Form 10-Q Financial Statement

#000148500319000065 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM
Carisma Therapeutics Inc Stock $carm